AIM ImmunoTech (AMEX:AIM) Stock, Quote.Headers.trade-ideas

AIM ImmunoTech

AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders and viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases, and the drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer, and triple-negative metastatic breast cancer. It is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.

Long Ideas

News

Penny Stocks

Insider Trades

Pre-Market Outlook

Markets

Trading Ideas

BCOV

PSIX

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIM ImmunoTech And 3 Other Stocks Under $3 Insiders Are Buying

BBGI

The Dow Jones closed lower by over 50 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

AIM ImmunoTech And 3 Other Stocks Under $1 Insiders Are Buying

CRYM

NTWK

The Dow Jones closed lower by more than 150 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

NetSol Technologies And 2 Other Stocks Under $2 Insiders Are Buying

AIM ImmunoTech Inc

Aimfinity Investment Corp I

Altra Industrial Motion Corp Com

Ainos Inc

Aimia Inc

AIMRITE HOLDINGS CORP by Aimrite Holdings Corporation

Aimrite Holdings Corp

AI / ML INNOVATIONS INC by AI / ML Innovations Inc.

AI/ML Innovations Inc

Immersed Inc

Biotech

General

AIM ImmunoTech Announces New Pre-Clinical Data Showing Ampligen As Part Of Combination Therapy Slows Melanoma Tumor Growth And Improves Survival In Mouse Model

Offerings

ImmunoTech Announces Pricing Of 5,640,958 Share Registered Direct Offering At $0.363 Per Share; Gross Proceeds ~$2M

Earnings

AIM ImmunoTech Q1 2024 GAAP EPS $(0.12), Inline, Sales $40.000K Down From $49.000K YoY

<a href="https://www.globenewswire.com/Tracker?data=NsDuXAQK-8KnOqGJ_1aIrLBwv1rT6uDwgHvZfXcRcWcrReUsza_WqdtVeM7-K_NtERPr9M4N5EhariW3Oyse4hiCU_Eb-pPRyNH0oiXkBoI=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today announced the successfully completion of cGMP manufacturing of 9,042 clinical vials of <a href="https://www.globenewswire.com/Tracker?data=yv2j6mxismSn9AAP-2p4SVNiVa_raIAy6VByPXo-20-bHPF_GkAVbPaQ3McX5dkJQKukpRieKlmtdBWb0F9FfA==">Ampligen</a>&#xAE; (rintatolimod), AIM's dsRNA product candidate being developed for globally important cancers, viral diseases and disorders of the immune system. &nbsp;
AIM Chief Executive Officer Thomas K. Equels commented, "We remain focused on operational execution and the successful continued production of our commercial-sized manufacturing process for Ampligen represents a critical component of our overall development, commercial and business development strategies. This is an important milestone as we look to advance our pipeline and work toward clinical and commercial success. Our record of successful manufacturing is both important as we seek commercial partners, as well as for establishing Ampligen reserves for ongoing and upcoming clinical trials."
Ampligen is currently being evaluated as a combinational therapy for the treatment of a variety of solid tumor types in multiple clinical trials – both underway and planned – at major cancer research centers around the country.
Ampligen has had a series of clinical trial advances in 2024. Read a recent update on <a href="https://www.globenewswire.com/Tracker?data=hOpToSK0zyeZOaml4OVtccTTnScxFfFp5-dXTwUWWHUWjfdI-f6kFxKJFaTIdxInwyrC_U4u-14nBQ5AaTGBDhlXHGd4Fi8UptnBTSlzevCmldK_Q61kaiv9ddF6WabK449gwWjsefg0b9XrGibgpoOw00D78rD3XMtoaVgEuPhWHOpPJi9NVWkGJ112aqjhqfwwi7vmylxDbWYDCSxfYoqtg0W7yVOTRc9j3mmfbe6OnjKBw55FY8kdznXyOiBk">AIM's active clinical study program</a>.

AIM ImmunoTech Completes cGMP Manufacturing Of Clinical Vials Of Ampligen

AIM ImmunoTech Complete Safety Evaluation Of Patents Enrolled For Phase 1b/2 Study Of Ampligen And Imfinzi As Combination Therapy For Late-Stage Pancreatic Cancer

AIM ImmunoTech Announces Top-Line, Protocol-Planned Interim Report Data From Study Of Ampligen Combined With Pembrolizumab For Recurrent Ovarian Cancer

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $(0.15) by 73.33 percent. This is a 188.89 percent decrease over losses of $(0.09) per share from the same period last year. The company reported quarterly sales of $65.00 thousand which beat the analyst consensus estimate of $40.00 thousand by 62.50 percent. This is a 16.07 percent increase over sales of $56.00 thousand the same period last year.

Earnings Beats

Earnings Misses

AIM ImmunoTech Q4 EPS $(0.26) Misses $(0.15) Estimate, Sales $65.00K Beat $40.00K Estimate

Health Care

AIM ImmunoTech Reported Cash, Cash Equivalents And Marketable Investments Of $13.1M, As Of December 31, 2023

<h3>Companies Reporting Before The Bell</h3>
&bull; Ocugen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCGN#NASDAQ">OCGN</a>) is estimated to report earnings for its fourth quarter.
&bull; Allego (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALLG#NYSE">ALLG</a>) is projected to report quarterly loss at $0.04 per share on revenue of $83.79 million.
&bull; Gryphon Digital Mining (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRYP#NASDAQ">GRYP</a>) is expected to report earnings for its fourth quarter.
&bull; AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report quarterly loss at $0.15 per share on revenue of $40 thousand.
&bull; Paychex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYX#NASDAQ">PAYX</a>) is expected to report quarterly earnings at $1.37 per share on revenue of $1.46 billion.
&bull; Abivax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABVX#NASDAQ">ABVX</a>) is likely to report quarterly loss at $2.14 per share on revenue of $4.88 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Cal-Maine Foods (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>) is projected to report quarterly earnings at $2.46 per share on revenue of $692.35 million.
&bull; Dave &amp; Buster&#39;s Enter (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLAY#NASDAQ">PLAY</a>) is likely to report quarterly earnings at $1.10 per share on revenue of $602.61 million.
&bull; Vicinity Motor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEV#NASDAQ">VEV</a>) is expected to report quarterly loss at $0.06 per share on revenue of $12.62 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ABVX

ALLG

CALM

GRYP

OCGN

PAYX

PLAY

Earnings Scheduled For April 2, 2024

AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) will release its quarterly earnings report on Tuesday, 2024-04-02. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate AIM ImmunoTech to report an earnings per share (EPS) of $-0.15.
Investors in AIM ImmunoTech are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Overview of Past Earnings</h3>
In the previous earnings release, the company missed EPS by $0.05, leading to a 3.55% increase in the share price the following trading session.
Here's a look at AIM ImmunoTech's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.11</td>
<td>-0.12</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.16</td>
<td>-0.10</td>
<td>-0.08</td>
<td>-0.09</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-3.0%</td>
<td>-0.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711994735_0.png" alt="eps graph" />
<h3>AIM ImmunoTech Share Price Analysis</h3>
Shares of AIM ImmunoTech were trading at $0.471 as of March 29. Over the last 52-week period, shares are up 5.57%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/AIM/earnings">To track all earnings releases for AIM ImmunoTech visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: AIM ImmunoTech's Earnings

<h3>Companies Reporting Before The Bell</h3>
&bull; bluebird bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLUE#NASDAQ">BLUE</a>) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
&bull; AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) is estimated to report earnings for its fourth quarter.
&bull; Elbit Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESLT#NASDAQ">ESLT</a>) is projected to report quarterly earnings at $1.38 per share on revenue of $1.52 billion.
&bull; GDS Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDS#NASDAQ">GDS</a>) is likely to report quarterly loss at $0.33 per share on revenue of $357.63 million.
&bull; Bragg Gaming Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRAG#NASDAQ">BRAG</a>) is estimated to report quarterly loss at $0.01 per share on revenue of $37.82 million.
&bull; BioLine Rx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLRX#NASDAQ">BLRX</a>) is expected to report earnings for its fourth quarter.
&bull; Zhihu (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZH#NYSE">ZH</a>) is likely to report quarterly loss at $0.04 per share on revenue of $148.11 million.
&bull; DouYu Intl Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOYU#NASDAQ">DOYU</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $170.91 million.
&bull; Waterdrop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WDH#NYSE">WDH</a>) is estimated to report quarterly earnings at $0.01 per share on revenue of $94.55 million.
&bull; Forza X1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRZA#NASDAQ">FRZA</a>) is likely to report earnings for its fourth quarter.
&bull; Acumen Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABOS#NASDAQ">ABOS</a>) is likely to report earnings for its fourth quarter.
&bull; Twin Vee PowerCats (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEEE#NASDAQ">VEEE</a>) is likely to report earnings for its fourth quarter.
&bull; Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is expected to report quarterly loss at $0.51 per share on revenue of $540 thousand.
&bull; Volato Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SOAR#AMEX">SOAR</a>) is estimated to report earnings for its fourth quarter.
&bull; Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) is likely to report quarterly earnings at $0.39 per share on revenue of $174.80 million.
&bull; Cognition Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGTX#NASDAQ">CGTX</a>) is estimated to report earnings for its fourth quarter.
&bull; McCormick &amp; Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MKC#NYSE">MKC</a>) is expected to report quarterly earnings at $0.58 per share on revenue of $1.56 billion.
&bull; Kaspi.kz (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KSPI#NASDAQ">KSPI</a>) is estimated to report earnings for its first quarter.
&bull; TD Synnex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNX#NYSE">SNX</a>) is likely to report quarterly earnings at $2.84 per share on revenue of $14.36 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) is estimated to report earnings for its fourth quarter.
&bull; Marpai (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRAI#NASDAQ">MRAI</a>) is estimated to report earnings for its fourth quarter.
&bull; NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) is likely to report quarterly loss at $0.30 per share on revenue of $3.40 million.
&bull; Aptose Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APTO#NASDAQ">APTO</a>) is projected to report earnings for its fourth quarter.
&bull; Direct Digital Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRCT#NASDAQ">DRCT</a>) is likely to report quarterly earnings at $0.26 per share on revenue of $65.95 million.
&bull; US Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USEG#NASDAQ">USEG</a>) is expected to report quarterly loss at $0.03 per share on revenue of $8.87 million.
&bull; X Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYF#NYSE">XYF</a>) is likely to report earnings for its fourth quarter.
&bull; Iridex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRIX#NASDAQ">IRIX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $14.90 million.
&bull; iPath Series B Carbon Exchange-Traded Notes (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRN#NYSE">GRN</a>) is projected to report quarterly loss at $0.01 per share on revenue of $13.40 million.
&bull; Intrusion (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTZ#NASDAQ">INTZ</a>) is likely to report quarterly loss at $0.11 per share on revenue of $1.64 million.
&bull; BioAtla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>) is expected to report earnings for its fourth quarter.
&bull; GameStop (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) is likely to report quarterly earnings at $0.29 per share on revenue of $2.05 billion.
&bull; Forge Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRGE#NYSE">FRGE</a>) is likely to report quarterly loss at $0.10 per share on revenue of $19.57 million.
&bull; Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) is expected to report earnings for its fourth quarter.
&bull; ProSomnus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OSA#NASDAQ">OSA</a>) is expected to report quarterly loss at $0.31 per share on revenue of $7.37 million.
&bull; ATA Creativity Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AACG#NASDAQ">AACG</a>) is likely to report earnings for its fourth quarter.
&bull; Noah Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOAH#NYSE">NOAH</a>) is estimated to report earnings for its fourth quarter.
&bull; PAVmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAVM#NASDAQ">PAVM</a>) is projected to report quarterly loss at $1.89 per share on revenue of $1.05 million.
&bull; AEye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIDR#NASDAQ">LIDR</a>) is likely to report quarterly loss at $1.20 per share on revenue of $100 thousand.
&bull; Velo3D (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VLD#NYSE">VLD</a>) is likely to report quarterly loss at $0.08 per share on revenue of $19.50 million.
&bull; Progress Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRGS#NASDAQ">PRGS</a>) is expected to report quarterly earnings at $1.14 per share on revenue of $181.91 million.
&bull; WidePoint (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/WYY#AMEX">WYY</a>) is estimated to report earnings for its fourth quarter.
&bull; LuxUrban Hotels (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUXH#NASDAQ">LUXH</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $34.20 million.
&bull; Oxbridge Re Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OXBR#NASDAQ">OXBR</a>) is expected to report earnings for its fourth quarter.
&bull; Concentrix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNXC#NASDAQ">CNXC</a>) is estimated to report quarterly earnings at $2.58 per share on revenue of $2.38 billion.
&bull; Ouster (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OUST#NYSE">OUST</a>) is likely to report quarterly loss at $0.83 per share on revenue of $24.06 million.
&bull; Ncino (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNO#NASDAQ">NCNO</a>) is expected to report quarterly earnings at $0.12 per share on revenue of $124.62 million.
&bull; PaySign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PAYS#NASDAQ">PAYS</a>) is projected to report quarterly earnings at $0.02 per share on revenue of $12.62 million.
&bull; Ryvyl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $18.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AACG

ABOS

APTO

BCAB

BIOR

BLRX

BLUE

BRAG

CGTX

CNXC

DCTH

DOYU

DRCT

ESLT

FRGE

FRZA

INTZ

IRIX

KSPI

LIDR

LUXH

MRAI

NCNO

NOAH

OUST

OXBR

PAVM

PAYS

PRGS

RVYL

SIDU

SOAR

USEG

VEEE

Earnings Scheduled For March 26, 2024

AIM ImmunoTech Announces Publication Of Findings From Study Evaluating Ampligen In Treatment Of Pancreatic Cancer In Journal Clinical Cancer Research

The Dow Jones index closed lower by over 300 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out <a href="https://www.benzinga.com/sec/insider-trades/"> Benzinga&#39;s insider transactions </a> platform.
<h3>Citizens </h3>
<ul>
<li>The Trade: Citizens, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cia#NYSE">CIA</a>) President and CEO Gerald Shields <a href="https://www.benzinga.com/quote/CIA/analyst-ratings"> acquired a total of 17,466 shares </a> an average price of $2.26. To acquire these shares, it cost around $39,475.</li>
<li>What&rsquo;s Happening: On March 18, Citizens, named Jon Stenberg as President of Citizens.</li>
<li>What Citizens Does: Citizens Inc is an insurance holding company serving the life insurance needs of individuals in the United States.</li>
</ul>
<h3>AIM ImmunoTech</h3>
<ul>
<li>The Trade: AIM ImmunoTech Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/aim#NYSE">AIM</a>) Director Nancy Bryan <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 38,462 shares at </a> at an average price of $0.39. To acquire these shares, it cost around $15,000.</li>
<li>What&rsquo;s Happening: On Feb. 8, AIM ImmunoTech reported topline results from Phase 2 study evaluating ampligen for the treatment of post-COVID conditions.</li>
<li>What AIM ImmunoTech Does: AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases.</li>
</ul>
Check This Out: <a href="https://www.benzinga.com/news/24/03/37889754/top-5-consumer-stocks-that-may-crash-this-month"> Top 5 Consumer Stocks That May Crash This Month </a>
<h3>Power Solutions International </h3>
<ul>
<li>The Trade: Power Solutions International, Inc. (OTC: <a class="ticker" href="https://www.benzinga.com/stock/psix#OTC">PSIX</a>) 10% owner Neil Gagnon <a href="https://www.benzinga.com/sec/insider-trades/"> acquired a total of 5,392 shares </a> at an average price of $2.00. The insider spent around $10,784 to buy those shares.</li>
<li>What&rsquo;s Happening: On March 14, Power Solutions International announced fourth quarter and full year 2023 financial results.</li>
<li>What Power Solutions International Does: Power Solutions International Inc is an America-based company that manufactures, distributes, and services power systems that primarily run on nondiesel fuels, including natural gas, propane, and gasoline.</li>
</ul>
<h3>Brightcove </h3>
<ul>
<li>The Trade: Brightcove Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bcov#NASDAQ">BCOV</a>) 10% owner Brolin Jonathan <a href="https://www.benzinga.com/quote/BCOV/analyst-ratings"> acquired a total of 30,000 shares </a> at an average price of $1.88. The insider spent around $56,250 to buy those shares.</li>
<li>What&rsquo;s Happening: On Feb. 22, Brightcove reported fourth-quarter financial results and issued FY24 guidance below estimates.</li>
<li>What Brightcove Does: Brightcove Inc is a provider of cloud-based streaming technology and services.</li>
</ul>
&nbsp;
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

CEO Corner segments to provide added perspective to press releases, corporate developments and pipeline progress &nbsp;
Provides interested parties the ability to ask questions and submit topics for future videos

AIM ImmunoTech Launches CEO Corner Platform

The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study with the full name "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy efficacy." The primary objective of the Phase 1b portion is to determine the safety of combination therapy with Imfinzi and Ampligen. The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy.

AIM ImmunoTech Announces First Subject Dosed In Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For Pancreatic Cancer

<h3>Gainers</h3>
<ul>
<li>BioSig Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSGM#NASDAQ">BSGM</a>) stock increased by 7.7% to $0.96 during Monday's after-market session. The company's market cap stands at $8.9 million. </li>
<li>Coeptis Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COEP#NASDAQ">COEP</a>) shares rose 6.64% to $0.48. The market value of their outstanding shares is at $16.3 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock rose 6.56% to $0.97. The market value of their outstanding shares is at $6.4 million. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock increased by 5.7% to $0.1. The company's market cap stands at $5.3 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares rose 5.54% to $0.45. The market value of their outstanding shares is at $21.9 million. </li>
<li>Better Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTTX#NASDAQ">BTTX</a>) stock moved upwards by 4.99% to $0.18. The company's market cap stands at $9.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>G1 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTHX#NASDAQ">GTHX</a>) stock fell 37.5% to $2.8 during Monday's after-market session. The market value of their outstanding shares is at $145.1 million. </li>
<li>InVivo Therapeutics Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVIV#NASDAQ">NVIV</a>) shares fell 12.07% to $0.28. </li>
<li>23andMe Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ME#NASDAQ">ME</a>) shares decreased by 10.64% to $0.69. The market value of their outstanding shares is at $332.2 million. The company's, Q3 earnings came out 3 days ago. </li>
<li>Calidi Biotherapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CLDI#AMEX">CLDI</a>) shares decreased by 10.04% to $0.52. The company's market cap stands at $18.4 million. </li>
<li>Beyond Air (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) shares decreased by 7.45% to $1.99. The market value of their outstanding shares is at $70.8 million. As per the news, the Q3 earnings report came out today. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) shares fell 6.61% to $3.11. The company's market cap stands at $19.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ALZN

BSGM

BTTX

CLDI

COEP

CPHI

GTHX

NVIV

SYRA

XAIR

12 Health Care Stocks Moving In Monday's After-Market Session

Efficacy results offer preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions &nbsp;
Safety results show Ampligen is generally well tolerated in the treatment of Post-COVID Conditions

AIM ImmunoTech Reports Topline Results From Phase 2 Study Evaluating Ampligen For Treatment Of Post-COVID Conditions

AIM ImmunoTech Receives Erasmus Medical Center Ethics Board Authorization For Phase 2 Study Of Ampligen For Treatment Of Locally Advanced Pancreatic Cancer

<h3>Gainers</h3>
<ul>
<li>Redhill Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDHL#NASDAQ">RDHL</a>) shares rose 11.1% to $0.99 during Tuesday's after-market session. The market value of their outstanding shares is at $19.4 million. </li>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 8.14% to $0.2. The company's market cap stands at $9.9 million. </li>
<li>Ensysce Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENSC#NASDAQ">ENSC</a>) shares increased by 7.29% to $1.47. The company's market cap stands at $4.6 million. </li>
<li>Moleculin Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBRX#NASDAQ">MBRX</a>) shares increased by 4.99% to $0.48. The company's market cap stands at $16.0 million. </li>
<li>Connect Biopharma Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNTB#NASDAQ">CNTB</a>) shares moved upwards by 4.83% to $1.3. The company's market cap stands at $71.5 million. </li>
<li>AIM ImmunoTech (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AIM#AMEX">AIM</a>) shares moved upwards by 4.65% to $0.45. The company's market cap stands at $21.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) stock decreased by 5.1% to $0.29 during Tuesday's after-market session. The company's market cap stands at $2.5 million. </li>
<li>Humacyte (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUMA#NASDAQ">HUMA</a>) shares fell 4.82% to $2.77. The company's market cap stands at $286.9 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) stock fell 4.81% to $0.42. The company's market cap stands at $18.7 million. </li>
<li>Cue Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLTH#NASDAQ">HLTH</a>) stock decreased by 4.53% to $0.21. The company's market cap stands at $32.6 million. </li>
<li>Aileron Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALRN#NASDAQ">ALRN</a>) stock decreased by 4.26% to $4.5. The company's market cap stands at $21.9 million. </li>
<li>Silk Road Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SILK#NASDAQ">SILK</a>) stock fell 3.91% to $14.26. The company's market cap stands at $555.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALRN

CNTB

ENSC

HLTH

HUMA

Intelligent Bio Solutions Inc. - Common Stock

INBS

MBRX

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

RDHL

SILK

SNTI

12 Health Care Stocks Moving In Tuesday's After-Market Session

<a href="https://www.globenewswire.com/Tracker?data=P0QSmVqfP3kS48Y7MMhzfpRCctBHZZJ4cW3JXgsDNBAD9xd0fdyoysrpgLDNA2WJFUGZcXZnZ2hf-IYEqB72u5idQ0X41ir5ttrHM5Z23Ao=">AIM ImmunoTech Inc.</a> (NYSE:<a href="https://www.benzinga.com/stock/AIM#NYSE">AIM</a>)&nbsp;("AIM" or the "Company") today announced that the first subject has been enrolled at Erasmus Medical Center ("Erasmus MC") in a Phase 1b/2 clinical trial combining AIM's Ampligen&#xAE; (rintatolimod) with AstraZeneca's anti-PD-L1 immune checkpoint inhibitor Imfinzi&#xAE; (durvalumab) for the treatment of late-stage pancreatic cancer (the "DURIPANC Study"). &nbsp;
Data strongly suggests Ampligen has therapeutic synergy when combined with checkpoint inhibitors — potentially increasing cancer treatment efficacy and subject survival rates. A successful DURIPANC Study could make AIM an especially attractive partnership or buyout target for Big Pharma. Data already strongly suggests that Ampligen synergistically enhances anti-PD-1 therapy. Strong positive clinical data from the DURIPANC study would also support our belief that Ampligen could synergistically enhance anti-PD-L1 therapies. Such broad-spectrum success could create value. AIM recently took an important step to secure potential stockholder value when it <a href="https://www.globenewswire.com/Tracker?data=q1tdxSnQJhWoOnztKRgQYaMHSzbFKfNrAWOWyVF-JTZe_h2kUC2oCS2jRLwfSzSLRs49oVU03MXk3fyRXowIfVsJzh2aHxHq9DuleHg5CIIuV5pj3IyB5Q4KsIMW8wNW3brzKGZacSCMHeRt0ye7IHatKpALeBcxBKaCpXAfix0m26hr23_USVT581DdS4VRZ9we5FvvwUuBoa42HbXIrUJ-4B-4CG7ZEsLTg63hXNo=">received a U.S. patent</a> for the use of Ampligen as part of a combination therapy with an anti-PD-L1 antibody, which is an immune checkpoint inhibitor that helps the body attack tumor cells.
The DURIPANC Study is an investigator-initiated, exploratory, open-label, single-center study with the full name "Combining anti-PD-L1 immune checkpoint inhibitor durvalumab with TLR-3 agonist rintatolimod in patients with metastatic pancreatic ductal adenocarcinoma for therapy effect." The primary objective of the Phase 1b portion is to determine the safety of combination therapy with Imfinzi and Ampligen. The primary objective of the Phase 2 portion is to determine the clinical benefit rate of the combination therapy.
"We expect to complete the Phase 1b portion of the study within six months," states Prof. Casper H.J. van Eijck, MD, PhD, the DURIPANC Study's Coordinating Investigator.
See <a href="https://www.globenewswire.com/Tracker?data=k59G02QetfB1hlhNYyMrNzk5SLpIsJSQhQuzh7vtsODeNrD5OJBYoN-xI7z6sgdGNG0d6Zxrss1jMd2RsLtd2gtFw8QB770_EsS6McDeq0G_aoMi2liqCb2jBsdh2Lfv39vYKY1EBBtHtSHkmGFHjQ==">ClinicalTrials.gov: NCT05927142</a> for more information.
AIM CEO Thomas K. Equels stated: "Ampligen's potential as part of a combination therapy is a relatively simple equation. One, elevated PD-L1 expression — which is known to occur in pancreatic cancer — has been associated with increased exhaustion of peripheral and intra-tumoral cytotoxic T cells, commonly called ‘killer' T cells. Two, data indicate that Ampligen has the potential to mitigate T cell exhaustion. Three, Ampligen can increase the number and activity of immune cells in the blood and tumor. And four, Imfinzi inhibits PD-L1 activity, thereby making those activated immune cells in the tumor microenvironment more effective at fighting the cancerous tumor. Data from our Dutch Early Access Program strongly supports Ampligen's potential to increase progression-free survival and overall survival. Our hope for the DURIPANC trial is that at a minimum we see an even longer period of stable disease, also called progression-free survival. However, we also believe this combination of drugs has the potential to decrease tumor size or even to cure the cancer, which is defined as being tumor free for at least five years. That would be a dramatic breakthrough in the treatment of a highly lethal and treatment-resistant human cancer."
The study is expected to enroll up to 18 subjects in its Phase 1b portion and up to 25 subjects in its Phase 2 portion. Subjects will start with Ampligen 200 mg via IV infusion twice per week for a total of 6 weeks (12 doses). Ampligen dose will be escalated to 400 mg according to a 3+3 DLT design. The first dose of Ampligen will be administered preferably 4-6 weeks after the last chemotherapy FOLFIRINOX dose. After two doses of Ampligen, the first dose of durvalumab 1500 mg via IV infusion will be introduced in week 2. Patients will continue to receive 1500 mg durvalumab via IV infusion every 4 weeks for up to a maximum of 48 weeks (up to 12 doses/cycles) with the last administration on week 48 or until confirmed disease progression according to Response Evaluation Criteria in solid Tumors (RECIST 1.1), unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met.

AIM ImmunoTech Announces That The First Subject Is Enrolled In The Phase 1b/2 Study Evaluating Ampligen In Combination With AstraZeneca's Imfinzi For The Treatment Of Late-Stage Pancreatic Cancer

AIM ImmunoTech files to sell 9.98M shares of common stock for holders

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on AIM ImmunoTech (AIM – Research Report) and Avid Bios...

Analysts Offer Insights on Healthcare Companies: AIM ImmunoTech (AIM) and Avid Bioservices (CDMO)

AIM ImmunoTech Q1 2024 Earnings Preview

Notable earnings before Thursday's open

AIM ImmunoTech GAAP EPS of -$0.12

AIM ImmunoTech Inc. (AIM) Q1 2024 Earnings Call Transcript

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
AIM ImmunoTech (NYSEMKT:<a href="https://investorplace.com/stock-quotes/aim-stock-quote/">AIM</a>) just reported results for the first quarter of 2024.<ul><li>AIM ImmunoTech reported earnings per share of -12 cents. This was below the analyst estimate for EPS of -11 cents.</li><li>The company reported revenue of $40,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/aim-stock-earnings-aim-immunotech-for-q1-of-2024/">AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

AIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024

Maxim Group analyst Jason McCarthy maintained a Buy rating on AIM ImmunoTech (AIM – Research Report) yesterday and set a price target of $2.00. Jas...

Buy Rating Affirmed: AIM ImmunoTech's Ampligen Shows Promising Oncology Pipeline Progress

AIM ImmunoTech announces pricing of $2.0M registered direct offering

AIM ImmunoTech files to sell 11.28M shares of common stock for holders

BIDU

CDMO

DTEGY

EDAP

GOOS

GORV

KNDI

LSPD

MGIC

NICE

OTLK

SIEGY

SSREY

VEON

XNET

ZURVY

Press Releases

AIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and Webcast

AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate Update

AIM ImmunoTech to Participate in Two Upcoming Investor Conferences

AIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering

AIM ImmunoTech to Participate in the Virtual Investor Lunch Break Series

Events

JTC Team Announces Participating Company Line-Up for the Virtual Investor Pitch Conference on June 17-18, 2024

AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference

Final Participating Company Line-Up Announced for the Virtual Investor Pitch Conference Hosted by JTC Team Being Held June 17 - 18, 2024

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

AIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination Therapy

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Comments

AIM ImmunoTech

AIM ImmunoTech (AIM) Forecast

AIM ImmunoTech (AMEX:AIM) Stock, Quote.Headers.trade-ideas